More recently, a clinical trial with the MUC1 100 mer peptide plus Hiltonol adjuvant enlisted a panel of new human anti-MUC1 antibodies that recognized the common PDTR minimal epitope with high affinity and exquisite in vitro anti-tumor effect and in vivo safety in human donors were reported [34]. This evidence concerns the gene MUC1 and neoplasm.